This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
by Zacks Equity Research
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
BOX Gears Up to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
BOX's fourth-quarter fiscal 2024 results are likely to reflect gains from the growing adoption of content cloud solutions.
Will Petrobras (PBR) Report Q4 Earnings Beat on Output Gains?
by Zacks Equity Research
Petrobras (PBR) beat the Zacks Consensus Estimate in two of the last four quarters and missed in the other two, which resulted in an earnings surprise of 3.8%, on average.
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
by Zacks Equity Research
Compugen (CGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
Baidu (BIDU) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Baidu's (BIDU) fourth-quarter results are likely to reflect the benefits of its AI business and growing autonomous driving efforts amid uncertainties in China.
Vipshop (VIPS) to Post Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Vipshop's (VIPS) fourth-quarter results are expected to reflect strength in its merchandising strategy and discount retail business amid macroeconomic challenges in China.
ACM Research (ACMR) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
ACM Research's (ACMR) fourth-quarter 2023 results are expected to reflect gains from semiconductor, ECP and advanced packaging businesses.
What to Look for in Crescent Point's (CPG) Q4 Earnings?
by Zacks Equity Research
Lower price realizations and an upward cost trajectory are likely to have dented Crescent Point Energy's (CPG) fourth-quarter results.
Agilent Technologies (A) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Agilent's (A) results for the fiscal first quarter are expected to reflect strength across ACG amid weakness in the LSAG and DGG segments.
What's in Store for Qurate Retail (QRTEA) in Q4 Earnings?
by Zacks Equity Research
Qurate Retail's (QRTEA) fourth-quarter 2023 results are likely to reflect strength in gardening, food and kitchen, and home decor categories.
Ginkgo (DNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Ginkgo's (DNA) fourth-quarter earnings call, investor focus is likely to be on the sales performance of its two business units, Biosecurity and Cell Engineering.
Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
by Zacks Equity Research
Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
by Zacks Equity Research
Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Compugen (CGEN) and Evogene (EVGN) have performed compared to their sector so far this year.
Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug
by Zacks Equity Research
If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studies support the FDA filing.
Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aspira (AWH) and Compugen (CGEN) have performed compared to their sector so far this year.
Has Compugen (CGEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Compugen (CGEN) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and Compugen (CGEN) have performed compared to their sector so far this year.
Is Certara (CERT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Certara, Inc. (CERT) and Compugen (CGEN) have performed compared to their sector so far this year.
Ensign Group (ENSG) Ups Credit Facility to $600M to Fuel Growth
by Zacks Equity Research
Ensign Group (ENSG) expands its credit facility by $250 million to continue with its series of acquisitions, renovation of projects, business requirements et al.
UnitedHealth (UNH) to Spend $5.4B on Home-Health Profile Boost
by Zacks Equity Research
UnitedHealth (UNH) intends to combine its Optum business with LHC Group to expand its reach in the healthcare-at-home market.
UnitedHealth (UNH) Arm Optum Acquires Refresh Mental Health
by Zacks Equity Research
UnitedHealth (UNH) unit Optum's acquisition of Refresh Mental Health comes at a time when demand for behavioral health services is on the rise.